Search
Atossa Therapeutics Inc
ATOSAdd to Watchlist
2.550USD
-0.030-1.16%
Market hours 08/31, 13:31（ET）
25.45MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-28The current earnings forecast score of Atossa Therapeutics Inc is 8.00, ranking 168 out of 377 in the Biotechnology & Medical Research industry. The average price target is 5.50, with a high of 8.00 and a low of 4.00.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
18.667
Target Price
+623.51%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Atossa Therapeutics Inc
ATOS
2
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
Kymera Therapeutics Inc
KYMR
24
IQVIA Holdings Inc
IQV
24
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Atossa Therapeutics Inc's price target?
Analysts forecast that Atossa Therapeutics Inc's price target is USD 5.50, with the highest forecast at USD 8.00 and the lowest forecast at USD 4.00.
How have Atossa Therapeutics IncATOS's recent earnings per share performed?
The market expectation was USD -0.95, while Atossa Therapeutics IncATOS's earnings per share (EPS) for the previous quarter was USD -1.11. EPS for the next quarter is expected at USD -0.94.
What is the analyst rating for Atossa Therapeutics Inc?
Based on the ratings of Atossa Therapeutics Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.